Aclaris Therapeutics (NASDAQ:ACRS) has been given a $50.00 price target by equities research analysts at Cantor Fitzgerald in a report released on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 102.27% from the stock’s current price.
The analysts wrote, “ACRS received approval for Eskata to treat SK. Although approval was expected by the Street, the timing comes ahead of the company’s 12/24 PDUFA date.””
A number of other equities analysts also recently issued reports on the company. Zacks Investment Research raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research note on Tuesday, October 10th. JMP Securities restated an “outperform” rating and issued a $39.00 price target on shares of Aclaris Therapeutics in a report on Friday, September 8th. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Aclaris Therapeutics presently has an average rating of “Hold” and an average price target of $39.20.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.23. The business had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $2.00 million. research analysts anticipate that Aclaris Therapeutics will post -2.59 earnings per share for the current year.
Large investors have recently made changes to their positions in the business. Citigroup Inc. grew its holdings in Aclaris Therapeutics by 171.8% during the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 2,726 shares during the last quarter. Legal & General Group Plc grew its holdings in Aclaris Therapeutics by 98.3% during the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after buying an additional 2,605 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Aclaris Therapeutics during the 3rd quarter valued at $142,000. Bank of Montreal Can boosted its holdings in shares of Aclaris Therapeutics by 1,793.1% during the second quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 6,760 shares during the last quarter. Finally, Voya Investment Management LLC acquired a new stake in shares of Aclaris Therapeutics during the second quarter worth $247,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Aclaris Therapeutics (ACRS) Given a $50.00 Price Target by Cantor Fitzgerald Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/15/aclaris-therapeutics-acrs-buy-rating-reaffirmed-at-cantor-fitzgerald.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.